References
1. Chang D, Xu H, Rebaza A, Sharma L, Dela Cruz CS. Protecting
health-care workers from subclinical coronavirus infection. Lancet
Respir Med . 2020;8(3):e13. doi:10.1016/S2213-2600(20)30066-7
2. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper
Respiratory Specimens of Infected Patients. N Engl J Med .
2020;382(12):1177-1179. doi:10.1056/NEJMc2001737
3. Lu D, Wang H, Yu R, Yang H, Zhao Y. Integrated infection control
strategy to minimize nosocomial infection of coronavirus disease 2019
among ENT healthcare workers. J Hosp Infect . February 2020.
doi:10.1016/j.jhin.2020.02.018
4. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface
Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J
Med . March 2020. doi:10.1056/NEJMc2004973
5. Ong SWX, Tan YK, Chia PY, et al. Air, Surface Environmental, and
Personal Protective Equipment Contamination by Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient.JAMA . March 2020. doi:10.1001/jama.2020.3227
6. Workman AD, Welling DB, Carter BS, et al. Endonasal instrumentation
and aerosolization risk in the era of COVID-19: simulation, literature
review, and proposed mitigation strategies. Int Forum Allergy
Rhinol . April 2020. doi:10.1002/alr.22577
7. Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia
associated with the 2019 novel coronavirus indicating person-to-person
transmission: a study of a family cluster. Lancet .
2020;395(10223):514-523. doi:10.1016/S0140-6736(20)30154-9
8. Lai C-C, Liu YH, Wang C-Y, et al. Asymptomatic carrier state, acute
respiratory disease, and pneumonia due to severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol
Immunol Infect . March 2020. doi:10.1016/j.jmii.2020.02.012
9. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV
Infection from an Asymptomatic Contact in Germany. N Engl J Med .
2020;382(10):970-971. doi:10.1056/NEJMc2001468
10. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2
infection: a nationwide analysis in China. Lancet Oncol .
2020;21(3):335-337. doi:10.1016/S1470-2045(20)30096-6
11. To KK-W, Tsang OT-Y, Chik-Yan Yip C, et al. Consistent detection of
2019 novel coronavirus in saliva. Clin Infect Dis . February 2020.
doi:10.1093/cid/ciaa149
12. Givi B, Schiff BA, Chinn SB, et al. Safety Recommendations for
Evaluation and Surgery of the Head and Neck During the COVID-19
Pandemic. JAMA Otolaryngol Head Neck Surg . March 2020.
doi:10.1001/jamaoto.2020.0780
13. Vukkadala N, Qian ZJ, Holsinger FC, Patel ZM, Rosenthal E. COVID-19
and the otolaryngologist - preliminary evidence-based review.Laryngoscope . March 2020. doi:10.1002/lary.28672
14. Berkelman RL, Holland BW, Anderson RL. Increased bactericidal
activity of dilute preparations of povidone-iodine solutions. J
Clin Microbiol . 1982;15(4):635-639.
15. Kawana R, Kitamura T, Nakagomi O, et al. Inactivation of human
viruses by povidone-iodine in comparison with other antiseptics.Dermatology (Basel) . 1997;195 Suppl 2:29-35.
doi:10.1159/000246027
16. Kariwa H, Fujii N, Takashima I. Inactivation of SARS coronavirus by
means of povidone-iodine, physical conditions and chemical reagents.Dermatology (Basel) . 2006;212 Suppl 1:119-123.
doi:10.1159/000089211
17. Eggers M, Eickmann M, Zorn J. Rapid and Effective Virucidal Activity
of Povidone-Iodine Products Against Middle East Respiratory Syndrome
Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA).Infect Dis Ther . 2015;4(4):491-501. doi:10.1007/s40121-015-0091-9
18. Eggers M, Koburger-Janssen T, Eickmann M, Zorn J. In Vitro
Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash
Against Respiratory and Oral Tract Pathogens. Infect Dis Ther .
2018;7(2):249-259. doi:10.1007/s40121-018-0200-7
19. Shiraishi T, Nakagawa Y. Evaluation of the bactericidal activity of
povidone-iodine and commercially available gargle preparations.Dermatology (Basel) . 2002;204 Suppl 1:37-41.
doi:10.1159/000057723
20. Nagatake T, Ahmed K, Oishi K. Prevention of respiratory infections
by povidone-iodine gargle. Dermatology (Basel) . 2002;204 Suppl
1:32-36. doi:10.1159/000057722
21. Tsuda S, Soutome S, Hayashida S, Funahara M, Yanamoto S, Umeda M.
Topical povidone iodine inhibits bacterial growth in the oral cavity of
patients on mechanical ventilation: a randomized controlled study.BMC Oral Health . 2020;20(1):62. doi:10.1186/s12903-020-1043-7
22. Okuda M, Kaneko Y, Ichinohe T, Ishihara K, Okuda K. Reduction of
potential respiratory pathogens by oral hygienic treatment in patients
undergoing endotracheal anesthesia. J Anesth . 2003;17(2):84-91.
doi:10.1007/s005400300022
23. Seguin P, Tanguy M, Laviolle B, Tirel O, Mallédant Y. Effect of
oropharyngeal decontamination by povidone-iodine on
ventilator-associated pneumonia in patients with head trauma. Crit
Care Med . 2006;34(5):1514-1519. doi:10.1097/01.CCM.0000214516.73076.82
24. Adamietz IA, Rahn R, Böttcher HD, Schäfer V, Reimer K, Fleischer W.
Prophylaxis with povidone-iodine against induction of oral mucositis by
radiochemotherapy. Support Care Cancer . 1998;6(4):373-377.
doi:10.1007/s005200050179
25. Ader AW, Paul TL, Reinhardt W, et al. Effect of mouth rinsing with
two polyvinylpyrrolidone-iodine mixtures on iodine absorption and
thyroid function. J Clin Endocrinol Metab . 1988;66(3):632-635.
doi:10.1210/jcem-66-3-632
26. Panchmatia R, Payandeh J, Al-Salman R, et al. The efficacy of
diluted topical povidone-iodine rinses in the management of recalcitrant
chronic rhinosinusitis: a prospective cohort study. Eur Arch
Otorhinolaryngol . 2019;276(12):3373-3381.
doi:10.1007/s00405-019-05628-w
27. Ramezanpour M, Smith JLP, Psaltis AJ, Wormald PJ, Vreugde S. In
vitro safety evaluation of a povidone-iodine solution applied to human
nasal epithelial cells. Int Forum Allergy Rhinol . April 2020.
doi:10.1002/alr.22575
28. Kim JH, Rimmer J, Mrad N, Ahmadzada S, Harvey RJ. Betadine has a
ciliotoxic effect on ciliated human respiratory cells. J Laryngol
Otol . 2015;129 Suppl 1:S45-50. doi:10.1017/S0022215114002746
29. Gluck U, Martin U, Bosse B, Reimer K, Mueller S. A clinical study on
the tolerability of a liposomal povidone-iodine nasal spray:
implications for further development. ORL J Otorhinolaryngol Relat
Spec . 2007;69(2):92-99. doi:10.1159/000097758
30. Safety & Efficacy Information 3M Skin and Nasal Antiseptic. March
2015.
https://multimedia.3m.com/mws/media/716788O/3m-skin-and-nasal-antiseptic-safety-and-efficacy-brochure.pdf.
Accessed April 6, 2020.
31. Singh S, Blakley B. Systematic review of ototoxic pre-surgical
antiseptic preparations - what is the evidence? J Otolaryngol Head
Neck Surg . 2018;47(1):18. doi:10.1186/s40463-018-0265-z
32. Ferguson AW, Scott JA, McGavigan J, et al. Comparison of 5%
povidone-iodine solution against 1% povidone-iodine solution in
preoperative cataract surgery antisepsis: a prospective randomised
double blind study. Br J Ophthalmol . 2003;87(2):163-167.
doi:10.1136/bjo.87.2.163
33. Hemani ML, Lepor H. Skin preparation for the prevention of surgical
site infection: which agent is best? Rev Urol .
2009;11(4):190-195.
34. Gultz J, Kaim JM, DeLeo J, Scherer W. An in vivo comparison of the
antimicrobial activities of three mouthrinses. J Clin Dent .
1998;9(2):43-45.
35. Bailey A, Longson M. Virucidal activity of chlorhexidine on strains
of Herpesvirus hominis, poliovirus, and adenovirus. J Clin
Pathol . 1972;25(1):76-78. doi:10.1136/jcp.25.1.76
36. Bernstein D, Schiff G, Echler G, Prince A, Feller M, Briner W. In
vitro virucidal effectiveness of a 0.12%-chlorhexidine gluconate
mouthrinse. J Dent Res . 1990;69(3):874-876.
doi:10.1177/00220345900690030901
37. Baqui AA, Kelley JI, Jabra-Rizk MA, Depaola LG, Falkler WA, Meiller
TF. In vitro effect of oral antiseptics on human immunodeficiency
virus-1 and herpes simplex virus type 1. J Clin Periodontol .
2001;28(7):610-616. doi:10.1034/j.1600-051x.2001.028007610.x
38. Geller C, Varbanov M, Duval RE. Human coronaviruses: insights into
environmental resistance and its influence on the development of new
antiseptic strategies. Viruses . 2012;4(11):3044-3068.
doi:10.3390/v4113044
39. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of
coronaviruses on inanimate surfaces and their inactivation with biocidal
agents. J Hosp Infect . 2020;104(3):246-251.
doi:10.1016/j.jhin.2020.01.022